MedTrace Logo

Echinaforce Junior Bioavailability Trial

NCT03070314 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-07-18

No results posted yet for this study

Summary

In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets.

Conditions

  • Common Cold

Interventions

DRUG

Echinaforce junior

Echinacea Purpurea Extract Pill, sweetened and with orange flavour

Sponsors & Collaborators

  • University Children's Hospital, Zurich

    collaborator OTHER

  • A. Vogel AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03070314 on ClinicalTrials.gov